新版基本医保药品目录正式实施 各地推动创新药尽快落地满足患者用药需求

Core Points - The new version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory has been officially implemented, adding 114 new drugs to the reimbursement list [1] - The new drug directory includes innovative drugs in key areas such as oncology, chronic diseases, pediatrics, and rare diseases, with some drugs being included within a year of their market launch [1] - Local medical insurance departments are actively promoting the implementation of the new drug directory, ensuring that designated medical institutions reasonably allocate and use the listed drugs [1] Group 1 - The new drug directory significantly reduces the financial burden on patients, as exemplified by a patient with triple-negative breast cancer who benefits from the inclusion of the drug Lukanosumab [1] - The new directory features innovative drugs like the world's first dual-target receptor agonist, Teriparatide injection, which has been included shortly after its market introduction [1] - Medical institutions, such as Hebei Medical University First Hospital, have adjusted drug prices in accordance with the new directory, leading to substantial price reductions for certain cancer and innovative mechanism drugs [1] Group 2 - Over 100,000 designated retail pharmacies across the country serve as a "double insurance" for patients, allowing them to purchase certain rare disease and innovative drugs with insurance reimbursement [2] - A commercial health insurance innovative drug directory has also been implemented, with ongoing collaboration among financial regulation, health, and other departments to support the expansion of commercial insurance coverage for innovative drug products [2] - The Beijing Medical Insurance Bureau is working to provide similar support policies for eligible commercial insurance products, facilitating their integration into the healthcare system [2]